Editorial: clinical outcomes in lean NAFLD - the devil is in the details. Authors' reply
- PMID: 37053482
- PMCID: PMC10707450
- DOI: 10.1111/apt.17453
Editorial: clinical outcomes in lean NAFLD - the devil is in the details. Authors' reply
Conflict of interest statement
Disclosures:
The authors’ declarations of personal conflicts of interest are unchanged from those in the original article.
Comment on
-
Higher mortality among lean patients with non-alcoholic fatty liver disease despite fewer metabolic comorbidities.Aliment Pharmacol Ther. 2023 May;57(9):1014-1027. doi: 10.1111/apt.17424. Epub 2023 Feb 23. Aliment Pharmacol Ther. 2023. PMID: 36815445 Free PMC article.
-
Editorial: clinical outcomes in lean NAFLD-the devil is in the details.Aliment Pharmacol Ther. 2023 May;57(9):1040-1041. doi: 10.1111/apt.17449. Aliment Pharmacol Ther. 2023. PMID: 37053487 No abstract available.
References
-
- Tan EX, Muthiah MD, Ng CH, Huang DQ. Editorial: clinical outcomes in lean NAFLD – the key may be in the details. Aliment Pharmacol Ther. 2023. - PubMed
-
- Kang KA, Jun DW, Kim MS, Kwon HJ, Nguyen MH. Prevalence of significant hepatic fibrosis using magnetic resonance elastography in a health check-up clinic population. Aliment Pharmacol Ther. 2020;51(3):388–396. - PubMed
-
- Harris R, Harman DJ, Card TR, Aithal GP, Guha IN. Prevalence of clinically significant liver disease within the general population, as defined by non-invasive markers of liver fibrosis: a systematic review. Lancet Gastroenterol Hepatol. 2017;2(4):288–297. - PubMed
-
- DiBattista JV, Burkholder DA, Lok AS, Chen VL. Accuracy of Non-invasive Indices for Diagnosing Hepatic Steatosis Compared to Imaging in a Real-World Cohort. Digestive Diseases and Sciences. 2022. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical